December 2025 in “Instituto Politécnico do Porto” Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.
5 citations
,
August 2021 in “Frontiers in Cell and Developmental Biology” DHEA boosts bone cell growth and differentiation in elderly stem cells.
Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.
8 citations
,
July 2024 in “Journal of Advanced Research” CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
50 citations
,
October 1986 in “European journal of pediatrics” A boy with severe Vitamin D-resistant rickets did not respond to treatment and lacked a common symptom, suggesting a need for alternative treatments.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
1 citations
,
November 2023 in “SKIN The Journal of Cutaneous Medicine”
2 citations
,
July 2023 in “Phytotherapy Research” Serenoa repens is mostly safe but has some risks, especially at high doses or when used with other products for over two weeks.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
August 2012 in “Pharmaceutical Medicine” The document concludes that various medications and treatments can have significant, sometimes adverse, effects on health outcomes.
May 2018 in “Dermatologic Surgery”
These medications for BPH have known risks and may have new side effects.
2 citations
,
May 2013 in “The primary care companion for CNS disorders” A teenage girl's excessive hair growth was caused by a medication for mania, but improved after stopping the medication.
January 2025 in “Buleria (Universidad de León)”
3 citations
,
July 2021 in “Drug Testing and Analysis” 5α-reductase inhibitors can interfere with doping tests by masking banned substances.
48 citations
,
November 1992 in “Clinical Endocrinology” Long-term finasteride use doesn't change bone density or metabolism.
32 citations
,
May 2013 in “The Journal of Urology” Using finasteride or dutasteride does not increase the risk of male breast cancer.
March 2026 in “American Journal of Clinical Dermatology”
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
February 2020 in “Definitions” 5 Alpha-Reductase Inhibitors reduce the effects of testosterone by blocking its conversion into a stronger form.
5 citations
,
June 2001 in “Annals of Internal Medicine” Rituximab effectively treated a woman's bone lymphoma that was resistant to other treatments.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
1 citations
,
April 2019 in “Reumatología Clínica (English Edition)” Leflunomide and methotrexate are similarly effective for rheumatoid arthritis but have different side effects.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.